BioXcel Therapeutics (BTAI) Enterprise Value Growth (1y) (2018 - 2026)
BioXcel Therapeutics (BTAI) Enterprise Value Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | BioXcel Therapeutics | 24.36 Mn | 24.36 Mn | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.70% |
| Mar 31, 2026 | 44.60% |
| Dec 31, 2025 | 3.67% |
| Sep 30, 2025 | 7.59% |
| Jun 30, 2025 | 66.99% |
| Mar 31, 2025 | 58.17% |
| Dec 31, 2024 | 54.23% |
| Sep 30, 2024 | 55.11% |
| Jun 30, 2024 | 55.88% |
| Mar 31, 2024 | 55.21% |
| Dec 31, 2023 | 66.33% |
| Sep 30, 2023 | 61.28% |
| Jun 30, 2023 | 45.37% |
| Mar 31, 2023 | 17.42% |
| Dec 31, 2022 | 16.84% |
| Sep 30, 2022 | 8.14% |
| Jun 30, 2022 | 14.50% |
| Mar 31, 2022 | -3.31% |
| Dec 31, 2021 | -9.31% |
| Sep 30, 2021 | -8.35% |